Sanofi and Regeneron’s pipeline-in-a drug Dupixent nabs priority review for yet another usenews2022-05-31T19:35:34+00:00May 31st, 2022|Fierce Pharma|
ASCO preview: How Gilead, Pfizer, AstraZeneca-Daiichi breast cancer data may—or may not—change treatment practicenews2022-05-31T16:03:33+00:00May 31st, 2022|Fierce Pharma|
After $500M IPO, HK inno.N enters exosome drug delivery via Ilias pactnews2022-05-31T14:34:32+00:00May 31st, 2022|Fierce Pharma|
Bavarian Nordic expects revenue boost after inking deals to supply monkeypox vaccine to more countriesnews2022-05-31T14:34:14+00:00May 31st, 2022|Fierce Pharma|
Roche’s Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newbornsnews2022-05-31T14:31:47+00:00May 31st, 2022|Fierce Pharma|
SciSparc unlocks nasal cannabinoid delivery via Polyrizon pactnews2022-05-31T14:03:16+00:00May 31st, 2022|Fierce Pharma|
Bristol Myers’ Opdivo fights Keytruda again with dual FDA nods in esophageal cancernews2022-05-31T13:54:35+00:00May 31st, 2022|Fierce Pharma|
MIT, Brigham push oral, oil-based delivery gel toward clinic to expand pediatric toolkitnews2022-05-31T12:48:39+00:00May 31st, 2022|Fierce Pharma|
Jubilant snags $146.6M US contract to double injectables productionnews2022-05-31T12:29:00+00:00May 31st, 2022|Fierce Pharma|
Novartis’ Kymriah bags FDA nod to face off against Gilead’s Yescarta in follicular lymphomanews2022-05-31T09:34:06+00:00May 31st, 2022|Fierce Pharma|
